JKJoslyn Sciacca Kirby

Joslyn Sciacca Kirby

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Joslyn Sciacca Kirby has a total of 218 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Insights from HS PROGRESS, a longitudinal registry of patients with Hidradenitis Suppurativa

    by Valdemar Wendelboe Nielsen, Michelle A. Lowes, Ashley Yates, Afsaneh Alavi, R. Hal Flowers, Iltefat Hamzavi, Kristen E. Holland, Joslyn Kirby, Robert Micheletti, Gretchen M. Roth, et al.

  • Open Access

    Incidence of Deep Vein Thrombosis and Pulmonary Embolism in Patients with Hidradenitis Suppurativa

    by Amit Garg, Joslyn Kirby, Theresa Amoloja, J. Morel Symons, Joseph Cordaro, Alex Silberzweig, Andrew Strunk

    Introduction The risk of thromboembolism in patients with hidradenitis suppurativa (HS) has not been established. This study aimed to estimate the incidence of deep vein thrombosis (DVT) and pulmonary embolism (PE) among adults with HS and demographic subgroups. Methods This retrospective cohort study was conducted between January 1, 2017, and December 31, 2024, using a health insurance claims database (Optum Clinformatics DataMart) in the US. Adults aged ≥ 18 years with an outpatient visit linked to a diagnosis of HS or any other diagnosis (controls) were eligible. Patients with prior diagnosis of either outcome or associated conditions were excluded. The primary outcomes evaluated were new-onset DVT and PE. Results Mean (SD) age was 43 (16) years for eligible patients with HS (n = 44,520) and 54 (19) years for control patients (n = 3,792,627). Incidence of DVT was 3.0 (95% CI 2.5–3.4) and 3.5 (95% CI 3.4–3.5) per 1000 person-years (PY) in patients with HS and controls, respectively. Incidence of PE was 2.4 (95% CI 2.0–2.8) and 2.2 (95% CI 2.2–2.3) per 1000 PY in patients with HS and controls, respectively. In demographics-adjusted analyses, standardized incidence ratios for DVT and PE were 1.42 (95% CI 1.23–1.65) and 1.78 (95% CI 1.50–2.10), respectively. Comorbidity-adjusted hazard ratios for DVT and PE were 1.12 (95% CI 0.97–1.31) and 1.35 (95% CI 1.14–1.60), respectively. Incidence of DVT was higher in patients with HS by a factor of 1.5–2.9 for age subgroups between 45 and 74 years, with absolute incidence rates ranging from 3.5 to 8.8 per 1000 PY. Incidence of PE was higher in patients with HS by a factor of 1.5–3.2 across age subgroups between 45 and 74 years, with absolute incidence rates ranging from 3.0 to 5.4 per 1000 PY. Conclusion Patients with HS have a significantly higher incidence of both DVT and PE relative to demographically similar patients without HS. This information may support counseling on risk mitigation strategies and safety monitoring during treatment and may provide context for observed (versus expected) thrombotic events in clinical trials for HS.

  • Pilot study of topical ruxolitinib demonstrates efficacy and blunting of heterogeneous inflammatory processes in mild hidradenitis suppurativa

    by Stephanie L Schell, Mackenzie L Sennett, Robert P Feehan, Tierney E Wallace, Elizabeth C Meiszberg, Amy L Longenecker, Matthew F Helm, Joslyn S Kirby, Amanda M Nelson

    Background: Therapeutic options for mild hidradenitis suppurativa (HS) represent a significant gap in the current treatment landscape, with no U.S. Food and Drug Administration-approved therapies for early-stage HS. Topical Janus kinase (JAK) inhibitors (JAKi) are a compelling option due to the known upregulation of inflammatory JAK signalling in HS lesions and the recent success of systemic JAKi for the treatment of moderate-to-severe HS. Objectives: To assess the clinical efficacy of ruxolitinib in a pilot cohort and to investigate the underlying biologic mechanisms associated with clinical response. Methods: This was a pilot single-site open-label prospective 24-week clinical trial of topical ruxolitinib (NCT04414514). Men and women with mild HS (Hurley stage I or II), with active inflammatory nodules, were recruited. All participants were observed for 8 weeks to monitor lesion counts (observational phase); active therapy (treatment phase) was then administered for 16 weeks. Topical ruxolitinib 1.5% cream was applied twice daily, covering the entirety of each HS-affected body site. Clinician- and patient-reported outcome measures were recorded throughout the study. Lesional skin punch biopsies were taken at the start and end of treatment for downstream mechanistic RNA sequencing and histological analyses. Results: Ten participants were enrolled in the study; four dropped out before the treatment phase of the trial. Six individuals with Hurley stage I (no tunnels) HS completed the study, five of whom successfully achieved Hidradenitis Suppurativa Clinical Response (HiSCR50) through 16 weeks of therapy. In this interim analysis, differential gene expression and gene set enrichment analyses revealed reduced activation of JAK-dependent interferon, interleukin (IL)-6, IL-2 and epidermal growth factor receptor signalling, and antimicrobial and keratinocyte responses. In contrast, signatures of wound healing and lipid metabolism were increased following JAKi treatment, indicating a return to homeostasis. Histological analyses revealed that clinically responsive patients had significantly reduced epidermal and dermal inflammation. Affected inflammatory infiltrate included neutrophils, T cells and plasma cells, with the predominantly affected cell types specific to the patient. Conclusions: Collectively, the broad activity of topical ruxolitinib on inflammatory signalling processes resulted in promising efficacy, even with heterogeneity in baseline inflammation, in this pilot cohort. Importantly, topical treatment not only resolved epidermal inflammation, but also cleared deeper inflammatory infiltrate. The observed efficacy provides rationale to further investigate topical JAKi and other novel topical treatments in HS.


  • Advances in Hidradenitis Suppurativa Pathogenesis and Therapies from the Symposium on HS Advances 2023

    by Sarah Park, Alexis Bell, Ruby Gibson, Rahul Masson, Steven Daveluy, Stephanie Goldberg, Jennifer Hsiao, Martina Porter, Joslyn Kirby, Vincent Piguet


  • Global consensus process to establish a core dataset for hidradenitis suppurativa registries

    by Hannah E Wainman, Nisha S Chandran, John W Frew, Amit Garg, Angela Gibbons, Athena Gierbolini, Barbara Horvath, Gregor B Jemec, Brian Kirby, Joselyn Kirby, et al.

    Background: Several registries for hidradenitis suppurativa (HS) already exist in Europe and the USA. There is currently no global consensus on a core dataset (CDS) for these registries. Creating a global HS registry is challenging, owing to logistical and regulatory constraints, which could limit opportunities for global collaboration as a result of differences in the dataset collected. The solution is to encourage all HS registries to collect the same CDS of information, allowing registries to collaborate. Objectives: To establish a core set of items to be collected by all HS registries globally. The core set will cover demographic details, comorbidities, clinical examination findings, patient-reported outcome measures and treatments. Methods: Beginning in September 2022, 20 participants – including both clinicians with expertise in HS and patient advocates – from eight countries across three continents participated in a Delphi process consisting of four rounds of voting, with all participants completing each round. A list of potential items for inclusion in the core set was generated from the relevant published literature, including systematic reviews of comorbidities in HS, clinical and examination findings, and epidemiology. For disease severity and progression items, the Hidradenitis SuppuraTiva Core outcome set International Collaboration (HiSTORIC) core set and other relevant instruments were considered for inclusion. This resulted in 47 initial items. Participants were invited to suggest additional items to include during the first round. Anonymous feedback was provided to inform each subsequent round of voting to encourage consensus. Results: The eDelphi process established a CDS of 48 items recommended for inclusion in all HS registries globally. Conclusions: The routine adoption of this CDS in current and future HS registries should allow registries in different parts of the world to collaborate, enabling research requiring large numbers of participants.


  • Open Access

    Efficacy and safety of the oral Janus kinase 1 inhibitor povorcitinib (INCB054707) in patients with hidradenitis suppurativa in a phase 2, randomized, double-blind, dose-ranging, placebo-controlled study

    by Joslyn S. Kirby, Martin M. Okun, Afsaneh Alavi, Falk G. Bechara, Christos C. Zouboulis, Kurt Brown, Leandro L. Santos, Annie Wang, Kristen B. Bibeau, Alexa B. Kimball, et al.


  • Open Access

    Understanding the real-world patient journey and unmet needs of people with hidradenitis suppurativa through social media research

    by Joslyn S Kirby, Antonio Martorell, Christopher J Sayed, Ivette Alarcon, Torben Kasparek, Susan Frade, Barry M McGrath, Bente Villumsen, Christos C Zouboulis

    People with hidradenitis suppurativa (HS) have a high burden of unmet needs and a better understanding of their lived experience is needed. Social media research is a novel approach that can improve such understanding by collecting and analysing publicly available information related to patient experiences. This study found that people with HS are unhappy with the management of their disease and highlights the need for greater awareness and research, as well as treatment effectiveness and options.


  • Initial validation of the Hidradenitis Suppurativa Quality of Life tool in a clinical trial setting

    by Leandro L Santos, Zhaoyin Zhu, Kurt Brown, Joslyn S Kirby

    We tested a new patient-reported outcome tool, the Hidradenitis Suppurativa Quality of Life (HiSQoL) questionnaire, which is designed to measure quality of life (QoL) in adults with hidradenitis suppurativa (HS). The HiSQoL demonstrated validity and reliability, and may be a useful tool for measuring QoL, especially in clinical trials testing new drugs in HS.


  • Positive Predictive Value of Diagnosis Codes for Hidradenitis Suppurativa and Cutaneous Abscess

    by Catherine Smiley, Andrew Strunk, Melissa Butt, Joslyn Kirby, Amit Garg

    Background: Requisite to the application of clinical databases for observational research in hidradenitis suppurativa (HS) is the identification of an accurate case cohort. There is limited information on the validity of using diagnosis codes to identify HS and cutaneous abscess (CA) case cohorts. Objectives: The objective of the study was to assess the validity in utilizing diagnosis codes to establish the HS and CA cohorts from an integrated health system clinical database. Methods: In this retrospective study, we evaluated a case-finding algorithm for HS which included the presence of at least one diagnosis code for HS and no diagnosis codes for CA of the axilla, groin, perineum, or buttock at any time. We evaluated a case-finding algorithm for CA which included the presence of at least one diagnosis code for abscess in the axilla, groin, perineum, or buttock and no codes for HS at any time. Medical records for a random sample of 100 patients meeting algorithm criteria were reviewed and adjudicated by dermatologists for accuracy of diagnosis. The positive predictive values (PPVs) of the ICD code-based case definitions were calculated, using the dermatologist’s chart-based adjudication as the reference standard. Results: Among 100 HS patients, median age (interquartile range) in the HS cohort was 33 (24.75, 43.25) years. HS patients were predominantly female (82%) and white (70%). Median age among 100 CA patients was 31.5 (95% CI 6.75, 47.25) years. The majority of CA patients were female (56%) and white (69%). The PPVs of the ICD-based case-finding algorithms for HS and CA were 88% (95% CI 81.6–94.4%) and 75.0% (95% CI 66.5–83.5%), respectively. Conclusion: The case-finding algorithms employing at least one diagnosis code for HS and CA of the axilla, groin, perineum, or buttock, with the exclusion of the other’s diagnosis codes, has good to strong PPV and may provide balance in achieving accuracy and adequate power for cohorts identified within clinical databases.


  • Open Access

    Demographic Gaps and Requirements for Participation: A Systematic Review of Clinical Trial Designs in Hidradenitis Suppurativa

    by JaBreia Fanita James, Victoria M. Madray, Nicole Salame, Samar Babikir Hasan, Mia Sohn White, Jason Richard Barron, Joslyn Kirby, John Robert Ingram, Lauren Anne Vigil Orenstein

    Background: Hidradenitis suppurativa (HS) is a chronic inflammatory disease that disproportionally affects women, as well as Black and biracial individuals. While adalimumab remains the only therapy approved by the Food and Drug Administration for HS, many HS clinical trials for novel and re-tasked therapies are ongoing or upcoming. To optimize treatment equity, reflect the patient population, and facilitate trial participation, it is important to elucidate aspects of clinical trial protocols that may systematically exclude specific patient groups or impose hardships. Objective: The study aimed to systematically review inclusion and exclusion criteria as well as participant demographics in HS clinical trials. Methods: A literature search of PubMed, Embase, Cochrane Central, and Web of Science databases was conducted. Peer-reviewed publications of randomized controlled trials that were written in English and had at least 10 participants were included. Title and abstract screening and data extraction were completed by two independent reviewers, with disagreements resolved by a third. Results: Twenty-three studies totaling 1,496 adult participants met the inclusion criteria. Race and ethnicity were not reported in 473/1,496 (31.6%) and 1,420/1,496 (94.9%) trial participants, respectively. Trial participants were predominantly white (811/1,023, 79.3%) and female (1,057/1,457, 72.5%). The median of each study’s average age was 35.7 years (IQR 33.5–38.0), and 17/23 (73.9%) trials excluded pediatric patients. Nearly all participants had Hurley Stage II (499/958, 52.0%) or Hurley Stage III (385/958, 40.2%) disease. Many trials excluded patients who were pregnant (19/23, 82.6%) and breastfeeding (13/23, 56.5%), or who had HS that was “too severe” (8/23, 34.8%) or “too mild” (16/23, 70.0%). Frequently, trial protocols required prolonged washout periods from HS therapies, relatively long duration in the study’s placebo arm, and prohibited concurrent analgesic use. Conclusions: This systematic review of 23 HS clinical trials totaling 1,496 participants identified substantial hardships imposed by trial participation, high rates of missing race and ethnicity data, and low representation of key patient groups, including those who identify as Black. Future trials with pragmatic study designs, broader inclusion criteria, and study sites in diverse communities may alleviate burdens of trial participation and improve enrollment of diverse patient groups.